Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 009″]

Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for glaucoma in late clinical trials.

Podcast Guest


Vicente Anido, Jr., PhD

Vicente Anido, Jr., PhD currently serves as CEO and Chairman of the Board of Aerie Pharmaceuticals, Inc., a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

View Full Profile